Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management
{{output}}
Introduction: The introduction of biosimilars changed the management of biologicals in inflammatory bowel disease (IBD) since the approval of CT-P13, the first biosimilar to infliximab, by the European Medicines Agency (EMA) in S... ...
